Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.

Yap TA, Nakagawa K, Fujimoto N, Kuribayashi K, Guren TK, Calabr? L, Shapira-Frommer R, Gao B, Kao S, Matos I, Planchard D, Chatterjee A, Jin F, Norwood K, Kindler HL. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med. 2021 06; 9(6):613-621.

View in: PubMed

collapse authors with profiles